Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
15 mai 2023 16h05 HE
|
Biora Therapeutics, Inc.
Completed execution of toxicology study for NaviCap™ BT-600 program with no adverse events indicated in preliminary data; on track to file IND in Q3 2023 Preclinical testing for the BioJet™ platform...
Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update
08 mai 2023 09h00 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report first quarter...
Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer
01 mai 2023 09h00 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the appointment of Ariella Kelman,...
Biora Therapeutics to Participate in Crohn’s & Colitis Foundation’s IBD Innovate Conference
20 avr. 2023 16h46 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, April 20, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will participate in IBD...
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
30 mars 2023 16h01 HE
|
Biora Therapeutics, Inc.
Biora initiating preclinical testing with pharma collaborator’s molecule following recent data exceeding the company’s target bioavailability levels for systemic therapeutics platform No adverse...
Biora Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
23 mars 2023 09h00 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report fourth...
Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist
23 févr. 2023 09h00 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced preliminary results from...
Biora Therapeutics Announces Improved Bioavailability Results for its Systemic Delivery Platform
16 févr. 2023 09h00 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced preliminary results from...
Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress
19 janv. 2023 16h05 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today presented detailed results from its PM-611...
Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023
09 janv. 2023 09h00 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced feedback from the United States...